Casandra
Casandra Test Code QD12523Version 1 (DRAFT)
Performing Lab
Antimicrobial Combinations, CF Panel
Clinical Use
Order TestUse
The use of antimicrobial combinations for the treatment of infectious diseases has become more common due to factors including more severe infections, development of organism resistance, and infection with multiple organisms. Antimicrobial combinations may help expand the spectrum of coverage, minimize drug toxicity, minimize development of resistance, and may lead to antimicrobial combination synergy.
Special Instructions
Not provided.
Limitations
Not provided.
Test Details
Methodology
Other
Biomarkers
12 targets
Cefepime and TobramycinCeftazidime and AmikacinImipenem and CiprofloxacinMeropenem and AmikacinMeropenem and CiprofloxacinPiperacillin and CiprofloxacinPiperacillin and TobramycinTobramycin and Aztreonam+4 more
Result Turnaround Time
4-6 days
Related Documents
For more information, please review the documents below
Specimen Requirements
Specimen
Other
Volume
Not provided
Minimum Volume
Not provided
Container
Pure isolate of Pseudomonas aeruginosa on a slant or transport swab
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | Determined by viability |
| Refrigerated | Determined by viability |
| Frozen | Unacceptable |
Similar Tests
Other tests from different labs that may be relevant
Minimum Inhibitory Concentration (MIC), Three Drugs
Labcorp
Susceptibility Testing, Aerobic and Facultatively Anaerobic Organisms
Labcorp
Antimicrobial Susceptibility, AFB/Mycobacterium tuberculosis Primary Panel
ARUP Laboratories
Antimicrobial Susceptibility, Nocardia species and other Aerobic Actinomycetes, Varies
Mayo Clinic Lab